CTOs on the Move


 
M2GEN is an oncology-focused bioinformatics solutions company advancing precision medicine and transforming cancer care through clinical and molecular data and analytics tools. The company`s innovative dataset accelerates the discovery, development, and delivery of personalized therapies. M2GEN`s Oncology Research Information Exchange Network® (ORIEN), an alliance of NCI-Designated cancer centers that gather de-identified and lifetime-consented clinical and genomic patient data for research purposes, enables a collaborative approach to the fight against cancer for patients today and tomorrow. M2GEN currently has more than 300,000 total consented patients across a network of 18 cancer centers in 10 states.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.m2gen.com
  • P.O. Box 5519
    Hudson, FL USA 34667
  • Phone: 813.384.5624

Executives

Name Title Contact Details
Daniel Elgort
Chief Data and Analytics Officer Profile
Karen Gispanski
Chief Information Security Officer Profile

Jobs

Chief Information Security Officer

M2Gen Remote
M2Gen is seeking a strong CISO to establish, develop, and grow our information security and privacy practice. Working closely with the CTO, executive leadership, and the broader organization, the ideal candidate brings in-depth knowledge of security focused software construction, security and privacy policy development and practice, solid understanding of ...

Similar Companies

BionorImmuno

BionorImmuno is a Bethesda, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Princeton BioMolecular Research Inc

Princeton BioMolecular Research Inc is a Monmouth Junction, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Viracta

Viracta is focused on advancing a proprietary viral gene activation therapy to address cancers associated with the Epstein-Barr Virus, and will pursue opportunities to address other serious virus-associated disease.

Okogen

Okogen serves the needs of adults and children with ocular infections by developing therapies to reduce suffering, improve quality of life, and preserve vision.

Syantra

With a cancer diagnosis, early detection means better outcomes. It means hope. But when it comes to breast cancer, more than half of women have a reduced opportunity for an early, life-saving diagnosis. That`s why we`re developing Syantra DX: a blood test to detect breast cancer. It`s a revolutionary, rapid, economical approach to breast cancer screening that`s accurate regardless of the test recipient`s family history, age or tissue density.